Sector News

Global green light for Merck KGaA/Sigma merger

August 12, 2015
Life sciences
Merck KGaA has been granted unconditional permission by regulatory authorities in Brazil to purchase US life sciences group Sigma-Aldrich, which means the firm has now secured approvals from all relevant jurisdictions for its planned acquisition.
 
The German drugmaker said it expects to complete the transaction sometime in the third quarter of this year, creating a business with combined sales of 4.7 billion euros (based on 2013 financials).
 
The timeframe for deal completion has been slightly extended to allow commitments made to the European Commission under its conditional approval of the deal – i.e. the sale of parts of Sigma-Aldrich’s solvents and inorganics business in the region – to be met.
 
The companies first unveiled their $17 billion merger in September last year, in a move to establish “one of the leading players in the $130 billion global life science industry,” with the ability to offer customers “a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products”, according to Merck.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”